Kiadis Pharma BV of the Netherlands has disclosed five-year follow-up data for an allogeneic stem cell treatment for patients undergoing transplantations for leukaemia which showed a survival rate of 67% at the optimal dose. The data has been submitted to a peer-reviewed medical journal for publication.
